Elsevier

The Lancet

Volume 343, Issue 8900, 26 March 1994, Pages 769-772
The Lancet

Clinical practice
Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

https://doi.org/10.1016/S0140-6736(94)91843-0Get rights and content

Abstract

Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) is known to increase substantially the risk of upper gastrointestinal bleeding and perforation (UGIB). We have carried out a population-based retrospective case-control study to assess the variation in risk associated with various individual NSAIDs, with adjustment for features of use and other independent risk factors. The study sample comprised 1457 cases of UGIB and 10 000 control subjects identified from general practitioners' computerised records in the UK. The adjusted estimate of relative risk of UGIB associated with current NSAID use was 4·7 (95% Cl 3·8-5·7). Previous UGIB was the single most important predictor of UGIB (relative risk 13·5 [10·3-17·7]). For all NSAIDs together, the risk was greater for high doses than for low doses (7·0 [5·2-9·6] vs 2·6 [1·8-3·8]). The estimates of risk associated with the individual NSAIDs varied widely. Users of azapropazone (23·4 [6·9-79·5]) and piroxicam (18·0 [8·2-39·6]) had the highest risk of UGIB among the NSAIDs studied. All the other NSAIDs with sufficient data for individual analysis (ibuprofen, naproxen, diclofenac, ketoprofen, and indomethacin) had relative risks similar to that for overall NSAID use. NSAIDS should be used cautiously in patients who have other risk factors for UGIB; these include advanced age, smoking, history of peptic ulcer, and use of oral corticosteroids or anticoagulants.

References (8)

  • CJ. Hawkey

    Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up?

    BMJ

    (1990)
  • P. Bollini et al.

    The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease

    Arch Intern Med

    (1992)
  • J. Jick et al.

    Validation of information recorded on general practitioner based computerised data resource in the United Kingdom

    BMJ

    (1991)
There are more references available in the full text version of this article.

Cited by (1004)

  • Pharmacokinetics-derived absorbed components responsible for Guizhi-Fuling capsule target PI3K/Akt-Erk to exert an anti-dysmenorrhea effect

    2022, Journal of Ethnopharmacology
    Citation Excerpt :

    As uterine-originating pain lacking pathology in the pelvic cavity (Kennedy, 1997), Primary dysmenorrhea (PD) is the most common reason for gynecologic visits, seriously affecting ∼90% of women's daily life (Kho and Shields, 2020). Nevertheless, the nonsteroidal anti-inflammatory drugs (NSAIDs), the first-line agent, have increasing adverse effects with long-term use involving cardiovascular injury (Schjerning et al., 2020), digestive disorders (García Rodríguez and Jick, 1994) and acute renal failure (Pérez Gutthann et al., 1996). Furthermore, oral contraceptives (OC) that inhibit prostaglandins can be an effective PD treatment, but they may be inappropriate for pregnant women (Hendrix and Alexander, 2002).

View all citing articles on Scopus
View full text